{"name":"Fundació Sant Joan de Déu","slug":"fundaci-sant-joan-de-d-u","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"HITS","genericName":"HITS","slug":"hits","indication":"Other","status":"phase_2"},{"name":"Antidepressants","genericName":"Antidepressants","slug":"antidepressants","indication":"Other","status":"marketed"},{"name":"Lactosa (placebo arm)","genericName":"Lactosa (placebo arm)","slug":"lactosa-placebo-arm","indication":"Placebo control arm in clinical trials","status":"phase_3"},{"name":"NICE","genericName":"NICE","slug":"nice","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Dinutuximab. Immunotherapy","genericName":"Dinutuximab. Immunotherapy","slug":"dinutuximab-immunotherapy","indication":"Neuroblastoma","status":"phase_2"},{"name":"citalopram (SSRI)","genericName":"citalopram (SSRI)","slug":"citalopram-ssri","indication":"Major depressive disorder","status":"marketed"}]}],"pipeline":[{"name":"HITS","genericName":"HITS","slug":"hits","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antidepressants","genericName":"Antidepressants","slug":"antidepressants","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dinutuximab. Immunotherapy","genericName":"Dinutuximab. Immunotherapy","slug":"dinutuximab-immunotherapy","phase":"phase_2","mechanism":"Monoclonal antibody targeting GD2","indications":["Neuroblastoma"],"catalyst":""},{"name":"Lactosa (placebo arm)","genericName":"Lactosa (placebo arm)","slug":"lactosa-placebo-arm","phase":"phase_3","mechanism":"Lactose is an inert sugar used as a placebo control in clinical trials and has no active pharmacological mechanism.","indications":["Placebo control arm in clinical trials"],"catalyst":""},{"name":"NICE","genericName":"NICE","slug":"nice","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"citalopram (SSRI)","genericName":"citalopram (SSRI)","slug":"citalopram-ssri","phase":"marketed","mechanism":"Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","indications":["Major depressive disorder","Panic disorder","Obsessive-compulsive disorder (off-label)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE13eGVqZ1pSQU03Wi1jTUg0LXIwNE0yQVV0clRadDFvUy1ROTRWUlZlaWhCa3Nhb3NsVnVWVFJkSnZWMmJBMFV2ZVU4Rjl0OF9wakhMWlUwa05JTFA5OTdv?oc=5","date":"2024-10-08","type":"pipeline","source":"Nature","summary":"Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy - Nature","headline":"Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9NYUFtMlpyQ3JQRk0tTjRpa1l5R0NTUFdXdE5mdUlTaXB1MnliZlcteDQ3Xy1WSWs1cGNxX2pIMm05MnJDblRzTmZLeUlOcENuWi1GZEFMZGg1ZEtMQ05QT29ac05mZ2NVSEdESFREdktqT2ZaT2g5Wk9UcERGUQ?oc=5","date":"2022-06-09","type":"pipeline","source":"PharmaLive","summary":"First Blood Test to Diagnose Bipolar Disorder - PharmaLive","headline":"First Blood Test to Diagnose Bipolar Disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNQ3llbFJ4ZXB6SzUwcXZsUnp3Yml1UjBrYnJBVkpCTGg5bzhyMmtxUURQYmdLaWdxa01ob0NxUlNoZkhoMUJoREFlYnlLSXQyU2NGN044eDIwaGlaemZpMUhOZ2JIZ2tGTmZHMEVZVDZfai1FRmhIU1ZZOWRvZ1BKMjdVUjVHemla?oc=5","date":"2021-04-18","type":"pipeline","source":"SciELO España","summary":"Antibiomania after triple therapy for Helicobacter Pylori: Two case reports and a review of physiopathology - SciELO España","headline":"Antibiomania after triple therapy for Helicobacter Pylori: Two case reports and a review of physiopathology - SciELO Esp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQYXltVVBBVWlDTTQ2c2hLSWdkalRYckZaMW5yN2lpVmdaLTRUUS1LVGdZZHVkTnpiX3BZS1hoSEpHTi1wTUtUMTVxenRpelNqNFMzYm1iOFlfMjN6R3ZSQlJsaUxhQWpFeFBHWGE3WmpiX3pHYmRsSk0zRmM4V1FmNG5tY25wOVhuOWMxNEY1LXJ0RUE3aVFyMFVWWUc5SUNEd1FSbmpSZXbSAa4BQVVfeXFMTWNoVndDTmIyX3ZnVmpCaFlDelBhUnRkOE1OOWhZak9leXFxU2VQT3RFWjNUbDRZSWNtSmFrQjRVanpjM1BGTWxlakJLQmlVdE90YUIzREJiMzhPeFZCSkcwVW1xY2dETUw2NDYxcUpvclNFWEV4bXNRMU1xUXd3aDlWYUo3QUhDVGlULTNObWR3VnMzSGZuS1ZfbDJ1aVJ5czZYcVJIYVlPN3RSUVNn?oc=5","date":"2021-02-10","type":"regulatory","source":"Diari ARA","summary":"Spain approves the use of CAR-T, the first public immunotherapy against leukaemia in Europe - Diari ARA","headline":"Spain approves the use of CAR-T, the first public immunotherapy against leukaemia in Europe","sentiment":"positive"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":2,"marketed":3,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}